Search
Midecamycin
go.drugbank.com/drugs/DB13456InvestigationalMidecamycin is a naturally occurring 16-membered macrolide that fits under the category of acetoxy-substituted macrolide antibiotics. In this molecule, an acetoxy group is substituted on the position 9 of the 16-member ring and on positi...
Synonyms: Turimycin P3Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsOtilonium
go.drugbank.com/drugs/DB13500InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesCloranolol
go.drugbank.com/drugs/DB13508ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesDiethyl ether
go.drugbank.com/drugs/DB13598InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 InducersDeltamethrin
go.drugbank.com/drugs/DB13600ExperimentalCategories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPentifylline
go.drugbank.com/drugs/DB13634ExperimentalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesSemustine
go.drugbank.com/drugs/DB13647InvestigationalCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesInfigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawnInfigratinib is a pan-fibroblast growth factor receptor (FGFR) kinase inhibitor. By inhibiting the FGFR pathway, which is often aberrated in cancers such as cholangiocarcinoma, infigratinib suppresses tumour growth. Cholangiocarcinoma is...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsApalutamide
go.drugbank.com/drugs/DB11901ApprovedInvestigationalApalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the tr...
Categories: P-glycoprotein inducers, Cytochrome P-450 CYP2C19 InducersValbenazine
go.drugbank.com/drugs/DB11915ApprovedInvestigationalValbenazine is a modified metabolite of tetrabenazine, and it is currently being approved for the treatment of various movement disorders, particularly tardive dyskinesia and chorea associated with Huntington's disease. Tardive dyskinesi...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates